Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Astria Therapeutics, Inc. - Common Stock (NQ:ATXS)

5.430 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 5.430
Bid (Size) 5.120 (2)
Ask (Size) 5.890 (1)
Prev. Close 5.430
Today's Range 5.430 - 5.430
52wk Range 3.555 - 12.92
Shares Outstanding 56,434,219
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Astria Therapeutics to Participate in Upcoming Oppenheimer Innovators in Immunology & Inflammation Summit
From Astria Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga

Performance

YTD
-39.5%
-39.5%
1 Month
+13.6%
+13.6%
3 Month
+0.6%
+0.6%
6 Month
-39.3%
-39.3%
1 Year
-41.3%
-41.3%

More News

Read More
Astria Therapeutics Announces Positive Initial Results from the ALPHA-SOLAR Long-Term Open-Label Trial of Navenibart in Hereditary Angioedema Patients at the European Academy of Allergy and Clinical Immunology Annual Congress
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Annual Congress
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics to Present at Upcoming Jefferies Global Healthcare Conference
From Astria Therapeutics
Via Business Wire
Astria Therapeutics to Present at Upcoming C1 Inhibitor Deficiency and Angioedema Workshop
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics to Present at Upcoming Eastern Allergy Conference
From Astria Therapeutics
Via Business Wire
Astria Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Announces Publication of Navenibart Phase 1a Healthy Subject Results in the Annals of Allergy, Asthma & Immunology
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics to Present at Upcoming Citizens Life Sciences Conference
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Initiates ALPHA-ORBIT Phase 3 Pivotal Trial of Navenibart in Hereditary Angioedema
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics to Present at Upcoming TD Cowen 45th Annual Health Care Conference
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma and Immunology and World Allergy Organization Joint Congress
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics to Present at Upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics to Present at Upcoming Western Society of Allergy, Asthma & Immunology Annual Scientific Session
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Announces Initiation of Phase 1a Trial of STAR-0310, a Potential Best-in-Class Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Announces Design of ALPHA-ORBIT Pivotal Phase 3 Trial of Navenibart in HAE
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga

Frequently Asked Questions

Is Astria Therapeutics, Inc. - Common Stock publicly traded?
Yes, Astria Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Astria Therapeutics, Inc. - Common Stock trade on?
Astria Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Astria Therapeutics, Inc. - Common Stock?
The ticker symbol for Astria Therapeutics, Inc. - Common Stock is ATXS on the Nasdaq Stock Market
What is the current price of Astria Therapeutics, Inc. - Common Stock?
The current price of Astria Therapeutics, Inc. - Common Stock is 5.430
When was Astria Therapeutics, Inc. - Common Stock last traded?
The last trade of Astria Therapeutics, Inc. - Common Stock was at 07/01/25 04:00 PM ET
What is the market capitalization of Astria Therapeutics, Inc. - Common Stock?
The market capitalization of Astria Therapeutics, Inc. - Common Stock is 306.44M
How many shares of Astria Therapeutics, Inc. - Common Stock are outstanding?
Astria Therapeutics, Inc. - Common Stock has 306M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.